» Articles » PMID: 29652078

Total Cardiovascular Events Analysis of the EXAMINE Trial in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome

Overview
Journal Clin Cardiol
Date 2018 Apr 14
PMID 29652078
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Alogliptin, a dipeptidyl peptidase-4 inhibitor, is approved for the treatment of patients with type 2 diabetes (T2DM). EXAMINE was a randomized controlled clinical trial designed to demonstrate the cardiovascular (CV) safety of alogliptin. In the trial, 5380 patients with established T2DM who had a recent acute coronary syndrome event (between 15 and 90 days) were randomized to treatment with either alogliptin or placebo. To better understand and describe the CV safety of alogliptin, we analyzed data from the EXAMINE trial to determine whether treatment with alogliptin affected recurrent and total CV events. Poisson regression analysis compared the total number of occurrences of CV death, MI, stroke, unstable angina, and coronary revascularization between all patients randomized to alogliptin vs placebo groups. Patients with recurrent CV events were older and more likely to have renal disease and history of heart failure. There were 1100 first CV events and an additional 666 recurrent events over a median of 18 months of follow-up. There were no significant differences with regard to total number of events in patients treated with alogliptin (n = 873) or placebo (n = 893; P = 0.52). Furthermore, there were no differences in the types of events seen in patients treated with alogliptin or placebo. Alogliptin did not increase the risk of either first or recurrent CV events when compared with placebo in patients with T2DM and recent acute coronary syndrome. These data support the CV safety of alogliptin in patients who are at increased risk of future CV events.

Citing Articles

Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.

Kanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y Cochrane Database Syst Rev. 2021; 10:CD013650.

PMID: 34693515 PMC: 8812344. DOI: 10.1002/14651858.CD013650.pub2.


Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.

Cavender M, White W, Liu Y, Massaro J, Bergenstal R, Mehta C Clin Cardiol. 2018; 41(8):1022-1027.

PMID: 29652078 PMC: 6489788. DOI: 10.1002/clc.22960.

References
1.
Hicks K, Tcheng J, Bozkurt B, Chaitman B, Cutlip D, Farb A . 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop.... J Am Coll Cardiol. 2015; 66(4):403-69. DOI: 10.1016/j.jacc.2014.12.018. View

2.
Zannad F, Cannon C, Cushman W, Bakris G, Menon V, Perez A . Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015; 385(9982):2067-76. DOI: 10.1016/S0140-6736(14)62225-X. View

3.
Feltner C, Jones C, Cene C, Zheng Z, Sueta C, Coker-Schwimmer E . Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med. 2014; 160(11):774-84. DOI: 10.7326/M14-0083. View

4.
Hess C, Clare R, Neely M, Tricoci P, Mahaffey K, James S . Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. Am Heart J. 2017; 187:194-203. DOI: 10.1016/j.ahj.2017.01.016. View

5.
Gaglia Jr M, Waksman R . Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor. Circulation. 2011; 123(4):451-6. DOI: 10.1161/CIRCULATIONAHA.110.985325. View